Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epidemiological studies suggest that, even in communities with high infection rates, herd immunity through natural infection may not have been achieved, and these studies raise the possibility that a combination of waning immunity and viral antigenic variation may allow for continued circulation of the virus11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Manaus experienced a strong wave of SARS-CoV-2 infection in April and May of 2020, which might have been expected to provide some level of protection or herd immunity in the exposed population. However, despite a low level of transmission from June to December 2020, a resurgence of infection was observed in early 2021 (refs11,57).”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with the seroepidemiological evidence for ongoing spread of infection in a highly exposed population in Manaus, which suggests that there may be susceptibility to reinfection after 6–8 months11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Several studies have estimated cumulative infections in select countries at specific points in time.6, 7, 8, 9”
From Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Self-citationFerguson, N. M., Laydon, D. J., Nedjati-Gilani, G. L., Imai, N., Ainslie, K. E. C., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z. M., Cuomo-Dannenburg, G., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77482 · Cited by 3,281
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,276
Empirical Likelihood and General Estimating Equations
Qin, J., & Lawless, J. (1994) · The Annals of Statistics · doi:10.1214/aos/1176325370 · Cited by 1,715
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
"Herd Immunity": A Rough Guide
Fine, P., Eames, K., & Heymann, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,247
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
ESTIMATING PREVALENCE FROM THE RESULTS OF A SCREENING TEST
ROGAN, W. J., & GLADEN, B. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112510 · Cited by 1,001
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Research works printed but not linked: 1
- 10.1186/1742-7622-9-9 · DOI
Cited by
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
“In practice we only consider symmetric cross-immunity βs = β, which is given the prior: β~Beta(2,1)”
BackgroundMethodInfluentialSelf-citationAge-specific mortality and immunity patterns of SARS-CoV-2
O’Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., & Salje, H. (2021) · Nature · doi:10.1038/s41586-020-2918-0 · Cited by 1,210
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00698-1 · Cited by 844
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758
Self-citationSensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651
“1 in an Amazon community that had presumptively achieved herd immunity (Buss et al., 2021; Sabino et al., 2021).”
BackgroundCOVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence
Naveca, F. G., Nascimento, V., de Souza, V. C., Corado, A. D. L., Nascimento, F., Silva, G., Costa, Á., Duarte, D., Pessoa, K., Mejía, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01378-7 · Cited by 462
Self-citationGangavarapu, K., Latif, A. A., Mullen, J. L., Alkuzweny, M., Hufbauer, E., Tsueng, G., Haag, E., Zeller, M., Aceves, C. M., Zaiets, K., et al. (2023) · Nature Methods · doi:10.1038/s41592-023-01769-3 · Cited by 394
“Regions of Brazil had attack rates as high as 75% in October 2020 [40], indicating that immune evasion was the primary reason for the rapid growth of the P.”
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
“1 SARSCoV-2 VOC despite an estimated seroprevalence of 75% in this region (Buss et al., 2021; Sabino et al., 2021).”
Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil
Voloch, C. M., da Silva Francisco, R., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. D. C., Mariani, D., da Costa, R. M., Ferreira, O. C., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00119-21 · Cited by 372
Novel SARS-CoV-2 variants: the pandemics within the pandemic
Boehm, E., Kronig, I., Neher, R. A., Eckerle, I., Vetter, P., & Kaiser, L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.022 · Cited by 345
“The pervasiveness may be due to immune escape in the context of a high level of population immunity [49].”
Spatiotemporal pattern of COVID-19 spread in Brazil
Castro, M. C., Kim, S., Barberia, L., Ribeiro, A. F., Gurzenda, S., Ribeiro, K. B., Abbott, E., Blossom, J., Rache, B., & Singer, B. H. (2021) · Science · doi:10.1126/science.abh1558 · Cited by 342
Self-citationThe variant gambit: COVID-19’s next move
Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328
Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00484-6 · Cited by 298
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.26.445838 · Cited by 266
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
Gómez, C. E., Perdiguero, B., & Esteban, M. (2021) · Vaccines · doi:10.3390/vaccines9030243 · Cited by 264
“The rapid increase in the number of hospital admissions by COVID-19 in January 2021 (six-fold higher than the number reported in December) [38] is unexpected and worrying considering that this city reached 76% seroprevalence during the summer wave [39].”
BackgroundDeng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Saad-Roy, C. M., Morris, S. E., Metcalf, C. J. E., Mina, M. J., Baker, R. E., Farrar, J., Holmes, E. C., Pybus, O. G., Graham, A. L., Levin, S. A., et al. (2021) · Science · doi:10.1126/science.abg8663 · Cited by 220
Self-citationBurden and characteristics of COVID-19 in the United States during 2020
Pei, S., Yamana, T. K., Kandula, S., Galanti, M., & Shaman, J. (2021) · Nature · doi:10.1038/s41586-021-03914-4 · Cited by 190
Medeiros-Ribeiro, A. C., Aikawa, N. E., Saad, C. G. S., Yuki, E. F. N., Pedrosa, T., Fusco, S. R. G., Rojo, P. T., Pereira, R. M. R., Shinjo, S. K., Andrade, D. C. O., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01469-5 · Cited by 202
Self-citationHitchings, M. D. T., Ranzani, O. T., Torres, M. S. S., de Oliveira, S. B., Almiron, M., Said, R., Borg, R., Schulz, W. L., de Oliveira, R. D., da Silva, P. V., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100025 · Cited by 197
Optimal levels of vaccination to reduce COVID-19 infected individuals and deaths: A global analysis
Coccia, M. (2022) · Environmental Research · doi:10.1016/j.envres.2021.112314 · Cited by 196
Pandemic Prevention: Lessons from COVID-19
Coccia, M. (2021) · Encyclopedia · doi:10.3390/encyclopedia1020036 · Cited by 190
“A delay of vaccination plan and of the achievement of optimal threshold within countries does not reduce transmission dynamics and can foster the emergence and diffusion of novel mutations of viral agents, such as in Brazil and India [69,70].”
BackgroundSARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation
Rajah, M. M., Hubert, M., Bishop, E., Saunders, N., Robinot, R., Grzelak, L., Planas, D., Dufloo, J., Gellenoncourt, S., Bongers, A., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108944 · Cited by 188
“…in the United Kingdom, Beta (B.1.351) identified in South Africa, Gamma (P.1 & P.2) identified in Brazil, and Delta (B.1.617.2) identified in India (preprint: Tegally et al , 2020; Buss et al , 2021; Frampton et al , 2021; Planas et al , 2021b; Sabino et al , 2021; preprint: Yadav et al , 2021).”
InfluentialPerkmann, T., Perkmann-Nagele, N., Koller, T., Mucher, P., Radakovics, A., Marculescu, R., Wolzt, M., Wagner, O. F., Binder, C. J., & Haslacher, H. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00247-21 · Cited by 185
Reduction in life expectancy in Brazil after COVID-19
Castro, M. C., Gurzenda, S., Turra, C. M., Kim, S., Andrasfay, T., & Goldman, N. (2021) · Nature Medicine · doi:10.1038/s41591-021-01437-z · Cited by 168
Self-citationSonabend, R., Whittles, L. K., Imai, N., Perez-Guzman, P. N., Knock, E. S., Rawson, T., Gaythorpe, K. A. M., Djaafara, B. A., Hinsley, W., FitzJohn, R. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02276-5 · Cited by 161
“…accounted for the effect of school holidays on transmission (except July 23–Sept 1, which overlaps with the period directly after step four where we assume a gradual increase in contacts) and seasonality in SARS-CoV-2 transmission (for full model description and data sources see appendix pp 3–6).”
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Castro Dopico, X., Ols, S., Loré, K., & Karlsson Hedestam, G. B. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 166
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 176
Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C. W., Weir, D. L., Kuzmina, N. A., Balinsky, C. A., Chen, H. W., Ewing, D. F., Schanoski, A. S., et al. (2021) · SSRN Electronic Journal · doi:10.1016/s2213-2600(21)00158-2 · Cited by 164
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
Peacock, T. P., Penrice-Randal, R., Hiscox, J. A., & Barclay, W. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001584 · Cited by 165
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 158
Gozzi, N., Tizzoni, M., Chinazzi, M., Ferres, L., Vespignani, A., & Perra, N. (2021) · Nature Communications · doi:10.1038/s41467-021-22601-6 · Cited by 142
COVID-19: Rethinking the Lockdown Groupthink
Joffe, A. R. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.625778 · Cited by 180
da Silva, S. J. R., & Pena, L. (2021) · One Health · doi:10.1016/j.onehlt.2021.100287 · Cited by 173
“The resurgence of COVID-19 was most notably seen first in Manaus, a large city in the middle of the Amazon Forest in Northern Brazil, where the massive number of hospitalizations and oxygen shortage collapsed the city ’ s health-care system resulting in a large number of deaths [2,11,12].”
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
Yan, Z., Yang, M., & Lai, C. (2021) · Pharmaceuticals · doi:10.3390/ph14050406 · Cited by 143
“Reinfection is still potentially possible [57].”
Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant
Coutinho, R. M., Marquitti, F. M. D., Ferreira, L. S., Borges, M. E., Lopes, R., Canton, O., Portella, T. P., Poloni, S., Franco, C. F. J., Pluciński, M. M., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00048-6 · Cited by 141
The false promise of herd immunity for COVID-19
Aschwanden, C. (2020) · Nature · doi:10.1038/d41586-020-02948-4 · Cited by 125
Coccia, M. (2023) · AIMS Public Health · doi:10.3934/publichealth.2023012 · Cited by 149
Ioannidis, J. P. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13554 · Cited by 127
de Souza, W. M., Amorim, M. R., Sesti‐Costa, R., Coimbra, L. D., Brunetti, N. S., de Toledo-Teixeira, D. A., de Souza, G. F., Muraro, S. P., Parise, P. L., Barbosa, P. P., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00129-4 · Cited by 119
Self-citationChanging composition of SARS-CoV-2 lineages and rise of Delta variant in England
Mishra, S., Mindermann, S., Sharma, M., Whittaker, C., Mellan, T. A., Wilton, T., Klapsa, D., Mate, R., Fritzsche, M., Zambon, M. C. F. A., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101064 · Cited by 120
“[10] Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.”
BackgroundInfluentialSelf-citationGrabowski, F., Preibisch, G., Giziński, S., Kochańczyk, M., & Lipniacki, T. (2021) · Viruses · doi:10.3390/v13030392 · Cited by 112
“1 strain led to the surge of infections in Manaus in December 2020 despite high seroprevalence of the population (a study of blood donors indicated that 76% [95% CI: 67–98%] of the population in Manaus had been infected with SARS‐CoV‐2 by October 2020 [20]).”
BackgroundCommunity-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals
Milman, O., Yelin, I., Aharony, N., Katz, R., Herzel, E., Ben‐Tov, A., Kuint, J., Gazit, S., Chodick, G., Patalon, T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01407-5 · Cited by 115
Is the cure really worse than the disease? The health impacts of lockdowns during COVID-19
Meyerowitz‐Katz, G., Bhatt, S., Ratmann, O., Brauner, J., Flaxman, S. R., Mishra, S., Sharma, M., Mindermann, S., Bradley, V., Vollmer, M., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-006653 · Cited by 112
One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview
Boschiero, M. N., Palamim, C. V. C., Ortega, M. M., Mauch, R. M., & Marson, F. A. L. (2021) · Annals of Global Health · doi:10.5334/aogh.3182 · Cited by 151
Xavier, D. R., Silva, E. L. E., Lara, F. A., Silva, G. R. R. E., de Oliveira, M. F., Gurgel, H., & Barcellos, C. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100221 · Cited by 117
Higher risk of death from COVID-19 in low-income and non-White populations of São Paulo, Brazil
Li, S. L., Pereira, R. H. M., Junior, C. A. P., Zarebski, A. E., Emanuel, L., Alves, P. J. H., Peixoto, P. S., Braga, C. K. V., Santos, A. A. D. S., de Souza, W. M., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-004959 · Cited by 111
Self-citationLee, W.-E., Woo Park, S., Weinberger, D. M., Olson, D., Simonsen, L., Grenfell, B. T., & Viboud, C. (2023) · eLife · doi:10.7554/elife.77562 · Cited by 90
COVID-19 transmission dynamics underlying epidemic waves in Kenya
Brand, S. P. C., Ojal, J., Aziza, R., Were, V. O., Okiro, E. A., Kombe, I. K., Mburu, C., Ogero, M. O., Agweyu, A., Warimwe, G. M., et al. (2021) · Science · doi:10.1126/science.abk0414 · Cited by 88
Álvarez-Antonio, C., Meza‐Sánchez, G., Calampa, C., Casanova, W., Carey, C., Alava, F., Rodríguez, H., & Quispe, A. M. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00173-x · Cited by 100
COVID-19 vaccines for low- and middle-income countries
Choi, E. M.-L. (2021) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trab045 · Cited by 89
Muena, N. A., García‐Salum, T., Pardo‐Roa, C., Avendaño, M. J., Serrano, E. F., Lévican, J., Almonacid, L. I., Valenzuela, G. H., Poblete, E., Strohmeier, S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103972 · Cited by 91
“…given the emergence of VOCs such as Gamma, and Delta, which have shown significant reduction in cross-reactive neutralizing titre, and have generated increased rates of re-infection in some regions of the world, 38 (cid:1) 40 a scenario that remains to be fully evaluated with the new VOC, Omicron.”
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 88
“The sharp increase in the total COVID-19 infections, followed by an increase in the number of hospital admissions observed in Manaus, indicate the high transmissibility of the variant [72,73].”
BackgroundBroadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
Shrestha, L. B., Tedla, N. T., & Bull, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752003 · Cited by 82
“1 (35, 41) show decreased susceptibility to some SARS-CoV-2 mAbs (11, 42–44), convalescent plasma (11, 45) and sera from SARS-CoV-2 vaccinees (11, 36, 44, 46, 47).”
BackgroundTackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78
“In this context, the resurgence of COVID-19 in Manaus, Brazil is associated with the emergence of the P.1 SARSCoV-2 VOC despite an estimated seroprevalence of 75% in this region (Buss et al., 2021; Sabino et al., 2021).”
Modelling and optimal control of multi strain epidemics, with application to COVID-19
Arruda, E. F., Das, S. S., Dias, C. M., & Pastore, D. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257512 · Cited by 90
“As the epidemic in Amazonas was largely unmitigated, with a high seroprevalence at the second peak [3, 46], it is consistent with a two-strain outbreak with reinfection, as demonstrated in Fig 2.”
BackgroundMethodResultInfluentialReyes-Vega, M. F., Soto-Cabezas, M. G., Cárdenas-Bustamante, F., Martel, K. S., Valle-Campos, A., Valverde, J., Vidal-Anzardo, M. H., Falcón, M. E., & Munayco, C. V. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100801 · Cited by 74
What the COVID-19 pandemic reveals about science, policy and society
Ball, P. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0022 · Cited by 76
COVID‐19 in Latin America and the Caribbean: Two years of the pandemic
Schwalb, A., Armyra, E., Méndez‐Aranda, M., & Ugarte‐Gil, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13499 · Cited by 86
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 72
Cantón, R., Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/071.2021 · Cited by 74
Linking excess mortality to mobility data during the first wave of COVID-19 in England and Wales
Basellini, U., Alburez‐Gutierrez, D., Fava, E. D., Perrotta, D., Bonetti, M., Camarda, C. G., & Zagheni, E. (2021) · SSM - Population Health · doi:10.1016/j.ssmph.2021.100799 · Cited by 64
Pelleau, S., Woudenberg, T., Rosado, J., Donnadieu, F., García, L., Obadia, T., Gardais, S., Elgharbawy, Y., Velay, A., Gonzalez, M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab375 · Cited by 65
Banho, C. Á., Sacchetto, L., Campos, G. R. F., Bittar, C., Possebon, F. S., Ullmann, L. S., Marques, B. D. C., da Silva, G. C. D., Moraes, M. M., Parra, M. C. P., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00108-5 · Cited by 66
Watson, O. J., Alhaffar, M., Mehchy, Z., Whittaker, C., Akil, Z., Brazeau, N. F., Cuomo-Dannenburg, G., Hamlet, A., Thompson, H. A., Baguelin, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22474-9 · Cited by 59
Self-citationHerd immunity by infection is not an option
Sridhar, D., & Gurdasani, D. (2021) · Science · doi:10.1126/science.abf7921 · Cited by 60
Chen, J., & Lu, H. (2021) · BioScience Trends · doi:10.5582/bst.2021.01092 · Cited by 60
“The rate of infection with SARS-CoV-2 was estimated to increase from 66% in June to 76% in October in Manaus based on seroprevalence data (5).”
BackgroundCovid-19 no Nordeste do Brasil: primeiro ano de pandemia e incertezas que estão por vir
Kerr, L. R. F. S., Kendall, C., de Almeida, R. L. F., Ichihara, M. Y., Aquino, E. M. L., da Sílva, A. A. M., Ximenes, R. A. D. A., de Albuquerque, M. D. F. P. M., Filho, N. D. A., Souza, R., et al. (2021) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2021055003728 · Cited by 85
Excess deaths associated with the Iranian COVID-19 epidemic: A province-level analysis
Ghafari, M., Kadivar, A., & Katzourakis, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.015 · Cited by 59
Herd immunity is an important—and often misunderstood—public health phenomenon
McDermott, A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107692118 · Cited by 69
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Clemens, S. A. C., Folegatti, P. M., Emary, K. R. W., Weckx, L. Y., Ratcliff, J., Bibi, S., Mendes, A. V. A., Milan, E. P., Pittella, A. M., Schwarzbold, A. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25982-w · Cited by 62
Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão
da Sílva, A. A. M., Neto, L. G. L., de Azevedo, C. D. M. P. E. S., da Costa, L. M. M., Bragança, M. L. B. M., Filho, A. K. D. B., Wittlin, B. B., de Souza, B. F., de Oliveira, B. L. C. A., de Carvalho, C. A., et al. (2020) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2020054003278 · Cited by 63
Codeço, C. T., Dal’Asta, A. P., Rorato, A. C., Lana, R. M., Neves, T. C., de Andreazzi, C. S., Barbosa, M., Escada, M. I. S., Fernandes, D. A., Rodrigues, D. L., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.647754 · Cited by 56
Lalwani, P. J., Salgado, B. B., Filho, I. V. P., da Silva, D. S. S., de Morais, T. B. D. N., Jordão, M. F., Barbosa, A. R. C., Cordeiro, I. B., Neto, J. N. D. S., de Assunção, E. N., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.017 · Cited by 60
Malta, M., Strathdee, S. A., & Garcia, P. J. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100757 · Cited by 69
“Pre-prints subsequently suggested that Manaus had achieved herd immunity [3].”
BackgroundPrioritizing COVID-19 vaccination by age
Castro, M. C., & Singer, B. H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103700118 · Cited by 56
Self-citationChivese, T., Matizanadzo, J. T., Musa, O. A. H., Hindy, G., Furuya‐Kanamori, L., Islam, N., Al-Shebly, R., Shalaby, R., Habibullah, M., Al-Marwani, T. A., et al. (2022) · Pathogens and Global Health · doi:10.1080/20477724.2022.2029301 · Cited by 55
Sun, K., Tempia, S., Kleynhans, J., von Gottberg, A., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., du Plessis, M., Carrim, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7081 · Cited by 52
Second wave of COVID-19 in Brazil: younger at higher risk
de Souza, F. S. H., Hojo-Souza, N. S., Silva, C. M., & Guidoni, D. L. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00750-8 · Cited by 55
“Such may indicate that the Amazon region, including the capital Manaus, may represent the “sentinel” population, as suggested by Buss et al [1].”
BackgroundMethodInfluentialSARS‐CoV‐2 seroprevalence among blood donors after the first COVID‐19 wave in Canada
Saeed, S., Drews, S. J., Pambrun, C., Yi, Q., Osmond, L., & O'Brien, S. F. (2021) · Transfusion · doi:10.1111/trf.16296 · Cited by 49
“Sixteen countries, from North America (n = 3), South America (n = 1), Europe (n = 7), Africa (n = 2), and Asia (n = 3) have reported preliminary seroprevalence findings among blood donors, ranging from as high as 66% in parts of Brazil to as low as 0% in Jordan.(19,20) Among the G8 countries, the United States (US) wa…”
BackgroundTemporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
Adetifa, I. M. O., Uyoga, S., Gitonga, J. N., Mugo, D., Otiende, M., Nyagwange, J., Karanja, H. K., Tuju, J., Wanjiku, P., Aman, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24062-3 · Cited by 67
SARS‐CoV‐2 virulence evolution: Avirulence theory, immunity and trade‐offs
Alizon, S., & Sofonea, M. T. (2021) · Journal of Evolutionary Biology · doi:10.1111/jeb.13896 · Cited by 59
“This epidemic was unexpected because it took place in Brazil and especially in the region of Manaus, where serological data suggested that, after a major health catastrophe, the cumulative incidence reached the theoretical herd immunity threshold (Buss et al., 2021).”
BackgroundGermanio, C. D., Simmons, G., Kelly, K. K., Martinelli, R., Darst, O., Azimpouran, M., Stone, M., Hazegh, K. E., Grebe, E., Zhang, S., et al. (2021) · Transfusion · doi:10.1111/trf.16555 · Cited by 44
“Such waning can be addressed by statistical adjustments in analyses, based on patterns of waning using CCP sample sets of findings from serial cross-sectional results, as recently done in a large study from Brazil based on the Abbott NC IgG assay included in the present study.(27) But these adjustments require paralle…”
ResultSelf-citationNowcasting epidemics of novel pathogens: lessons from COVID-19
Wu, J. T. K., Leung, K. S. M., Lam, T. T., Ni, M. Y., Wong, C. K. H., Peiris, M. J. S., & Leung, G. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01278-w · Cited by 53
Stone, M., Germanio, C. D., Wright, D. J., Sulaeman, H., Dave, H., Fink, R. V., Notari, E. P., Green, V., Strauss, D., Kessler, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab537 · Cited by 45
“persistence or waning has been shown to be assay-dependent (22), so it is essential to 241 select assays demonstrating durable antibody reactivity to accurately estimate cumulative 242 incidence based on serial cross-sectional seroprevalence data.”
Self-citationPerez-Saez, J., Zaballa, M.-E., Yerly, S., Andrey, D. O., Meyer, B., Eckerle, I., Balavoine, J.-F., Chappuis, F., Pittet, D., Trono, D., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.040 · Cited by 46
“Seroprevalence underestimation due to decaying sensitivity [4] will depend on the timing of serosurveillance with respect to the number and amplitude of preceding epidemic waves.”
Abela, I. A., Pasin, C., Schwarzmüller, M., Epp, S., Sickmann, M., Schanz, M., Rusert, P., Weber, J., Schmutz, S., Audigé, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27040-x · Cited by 46
COVID-19 mortality in Brazil, 2020-21: consequences of the pandemic inadequate management
Szwarcwald, C. L., Boccolini, C. S., de Almeida, W. D. S., Filho, A. M. S., & Malta, D. C. (2022) · Archives of Public Health · doi:10.1186/s13690-022-01012-z · Cited by 44
“In January 2021, Manaus experienced a severe health crisis, with a shortage of (mechanical) ventilators and hospital beds in Intensive Care Units (ICU), amid the dramatic lack of oxygen gas to treat people hospitalized with COVID-19 [22].”
BackgroundSupreme Court v. Necropolitics: The Chaotic Judicialization of COVID-19 in Brazil.
Biehl, J. G., Prates, L. E. A., & Amon, J. J. (2021) · Health and Human Rights · Cited by 59
Covid-19: Is Manaus the final nail in the coffin for natural herd immunity?
Taylor, L. (2021) · BMJ · doi:10.1136/bmj.n394 · Cited by 41
Sagara, I., Woodford, J., Koné, M., Assadou, M. H., Katilé, A., Attaher, O., Zéguimé, A., Doucoure, M., Higbee, E., Lane, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab589 · Cited by 46
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2
McConnell, D. J., Hickey, C., Bargary, N., Trela-Larsen, L., Walsh, C., Barry, M. G., & Adams, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094640 · Cited by 47
“Conversely, we have previously discussed the example of Manaus, Brazil, experiencing a resurgence of COVID-19 cases [10], despite evidence of possible herd immunity being attained [9].”
BackgroundRyu, D.-K., Kang, B., Noh, H., Woo, S., Lee, M., Nuijten, P. M., Kim, J., Seo, J.-M., Kim, C.-M., Kim, M., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.023 · Cited by 44
Zhang, Y., Gao, H., Hu, X., Wang, Q., Zhong, F., Zhou, X., Lin, C., Yang, Y., Wei, J., Du, W., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01253-21 · Cited by 40
Dopico, X. C., Muschiol, S., Christian, M., Hanke, L., Sheward, D. J., Grinberg, N. F., Rorbach, J., Bogdanović, G., McInerney, G. M., Allander, T., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13304 · Cited by 40
Hennis, A. J. M., Coates, A. R., del Pino, S., Ghidinelli, M., de León, R. G. P., Bolastig, E. V. C., Castellanos, L. D., Souza, R. O. E., & Luciani, S. (2021) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2021.130 · Cited by 40
Metadata
- Authors
- Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., Crispim, M. A. E., Ferreira, S. C., Fraiji, N. A., Gurzenda, S., Whittaker, C., Kamaura, L. T., Takecian, P. L., da Silva Peixoto, P., Oikawa, M. K., Nishiya, A. S., Rocha, V., Salles, N. A., de Souza Santos, A. A., da Silva, M. A., Custer, B., Parag, K. V., Barral-Netto, M., Kraemer, M. U. G., Pereira, R. H. M., Pybus, O. G., Busch, M. P., Castro, M. C., Dye, C., Nascimento, V. H., Faria, N. R., & Sabino, E. C.
- Affiliations
- Universidade de São Paulo (BR)
- Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (BR)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
- Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
- Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
- Harvard University (US)
- Imperial College London (GB)
- Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
- Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
- Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
- University of California, San Francisco (US)
- Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
- University of Oxford (GB)
- Institute of Applied Economic Research (BR)
- Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Corresponding author
- Buss, Lewis F.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- Faria, Nuno R.
- ORCID
- Buss, Lewis F.
- Prete, Carlos A.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- de Almeida-Neto, Cesar
- França, Rafael F. O.
- Belotti, Maria C.
- Carvalho, Maria P. S. S.
- Costa, Allyson G.
- Crispim, Myuki A. E.
- Ferreira, Suzete C.
- Fraiji, Nelson A.
- Gurzenda, Susie
- Whittaker, Charles
- Kamaura, Leonardo T.
- Takecian, Pedro L.
- da Silva Peixoto, Pedro
- Oikawa, Marcio K.
- Nishiya, Anna S.
- Rocha, Vanderson
- Salles, Nanci A.
- de Souza Santos, Andreza Aruska
- da Silva, Martirene A.
- Custer, Brian
- Parag, Kris V.
- Barral-Netto, Manoel
- Kraemer, Moritz U. G.
- Pereira, Rafael H. M.
- Pybus, Oliver G.
- Busch, Michael P.
- Castro, Márcia C.
- Dye, Christopher
- Nascimento, Vítor H.
- Faria, Nuno R.
- Sabino, Ester C.
- Venue
- Science
- Published
- 2021-01-15
- Volume
- 371
- Issue
- 6526
- Pages
- 288-292
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7857406
- OpenAlex
- W3112547455
- Cited by
- 488
- References
- 47
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 29 · 2023: 56 · 2022: 119 · 2021: 240
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/S0195/1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (18/14389-0)
- Itau Unibanco Todos pela Saude
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, attack rate, seroprevalence, immunoglobulin G antibodies, Manaus, Amazonas, antibody waning, blood donors, epidemic size estimation
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Female, Humans, Immunoglobulin G, Male, Middle Aged, Seroepidemiologic Studies, Young Adult, Epidemics, Epidemiological Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.